Design Therapeutics, Inc.
Business
Design Therapeutics is a clinical-stage biopharmaceutical company developing GeneTAC® molecules, a novel class of small-molecule gene targeted chimeras designed to treat genetic diseases caused by nucleotide repeat expansions. The company's lead programs target Friedreich ataxia, Fuchs endothelial corneal dystrophy, myotonic dystrophy type-1, and Huntington's disease, with candidates in Phase 1/2 clinical trials. GeneTAC® molecules are designed to be synthetically tractable, non-immunogenic small molecules that modulate transcription at the site of disease-causing mutations without altering the genome.
Summary from 10-K filed 2026-03-09
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Research and development (including related party amounts of $915 and $891, respectively) | 59 | 44 | 57 | 49 | 25 | |
| General and administrative (including related party amounts of $528 and $537, respectively) | 20 | 18 | 21 | 19 | 11 | |
| Total operating expenses | 79 | 62 | 78 | 68 | 36 | |
| Loss from operations | −79 | −62 | −78 | −68 | −36 | |
| Interest income | 10 | 13 | 11 | — | — | |
| Net loss | −70 | −50 | −67 | −63 | −36 | |
| Net loss per share, basic | −1.22 | −0.88 | −1.19 | −1.14 | −0.77 | |
| Net loss per share, diluted | −1.22 | −0.88 | −1.19 | −1.14 | −0.77 | |
| Weighted-average shares of common stock outstanding, basic | 57 | 57 | 56 | 56 | 46 | |
| Weighted-average shares of common stock outstanding, diluted | 57 | 57 | 56 | 56 | 46 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 17 | 23 | 21 | 27 | 299 | |
| Investment securities | 203 | 223 | 261 | 304 | 85 | |
| Prepaid expenses and other current assets | 4 | 3 | 3 | 5 | 1 | |
| Total current assets | 224 | 248 | 285 | 335 | 385 | |
| Property and equipment, net | 981,000 | 1 | 2 | 2 | 2 | |
| Right-of-use asset, related party | 1 | 2 | 3 | 4 | 4 | |
| Other assets | 0 | 427,000 | 430,000 | 459,000 | — | |
| Total assets | 226 | 252 | 290 | 341 | 391 | |
| Accounts payable | 2 | 2 | 2 | 3 | 2 | |
| Accrued expenses and other current liabilities (including related party amounts of $890 and $800, respectively) | 11 | 6 | 8 | 8 | 4 | |
| Total current liabilities | 13 | 8 | 10 | 11 | 5 | |
| Operating lease liability, net, related party | 645,000 | 2 | 2 | 3 | 3 | |
| Total liabilities | 14 | 10 | 12 | 14 | 8 | |
| Commitments and contingencies (See Note 11) | — | — | — | — | — | |
| Common stock: $0.0001 par value; 200,000,000 shares authorized, 60,398,051 and 56,754,341 shares issued and outstanding at December 31, 2025 and 2024, respectively | 6,000 | 6,000 | 6,000 | 6,000 | 6,000 | |
| Additional paid-in capital | 509 | 469 | 455 | 441 | 430 | |
| Accumulated deficit | −297 | −227 | −178 | −111 | −47 | |
| Accumulated other comprehensive income | 403,000 | 475,000 | 62,000 | −3 | −244,000 | |
| Total stockholders' equity | 213 | 242 | 278 | 327 | 382 | |
| Total liabilities and stockholders' equity | 226 | 252 | 290 | 341 | 391 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Net loss | −70 | −50 | −67 | −63 | −36 | |
| Depreciation | 622,000 | 596,000 | 537,000 | 406,000 | 129,000 | |
| Stock-based compensation | 15 | 13 | 13 | 11 | 5 | |
| Amortization of premiums on investment securities, net | −3 | −6 | −6 | −1 | −77,000 | |
| Non-cash lease expense | −21,000 | 6,000 | — | — | — | |
| Deferred financing costs | 427,000 | 0 | — | — | — | |
| Prepaid expense and other assets | −1 | 226,000 | 2 | −3 | −1 | |
| Accounts payable and other liabilities | 4 | −1 | −1 | 5 | 2 | |
| Net cash used in operating activities | −54 | −43 | −59 | −51 | −29 | |
| Purchases of investment securities | −292 | −230 | −225 | −313 | −86 | |
| Proceeds from maturities of investment securities | 315 | 274 | 277 | 93 | 34 | |
| Purchases of property and equipment | −193,000 | −340,000 | −256,000 | −918,000 | −2 | |
| Net cash provided by investing activities | 23 | 44 | 53 | −221 | −54 | |
| Proceeds from the issuance of common stock in at-the-market offering, net of issuance costs | 25 | 0 | — | — | — | |
| Proceeds from the exercise of stock options | 200,000 | 36,000 | 400,000 | 300,000 | 34,000 | |
| Issuance of common stock through employee stock purchase plan | 649,000 | 477,000 | 305,000 | 339,000 | 194,000 | |
| Net cash provided by financing activities | 26 | 513,000 | 724,000 | 235,000 | 379 | |
| Net decrease in cash and cash equivalents | −6 | 1 | −5 | −272 | 296 | |
| Issuance costs included in accrued expenses | 17,000 | 0 | — | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Design Therapeutics, Inc.'s CIK number?
Design Therapeutics, Inc.'s SEC CIK number is 0001807120 (1807120). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Design Therapeutics, Inc.'s SEC filings?
All of Design Therapeutics, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Design Therapeutics, Inc. last report earnings?
Design Therapeutics, Inc. (DSGN) most recently filed an earnings 8-K with the SEC on Apr 28, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-187012). This is Design Therapeutics, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Design Therapeutics, Inc.'s most recent earnings 8-K?
Design Therapeutics, Inc.'s latest earnings 8-K (Item 2.02) was filed Apr 28, 2026 under accession 0001193125-26-187012. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Design Therapeutics, Inc.'s latest earnings 8-K →
Look up any company's CIK number →